{"id":"efloxate","rwe":[{"pmid":"37184111","year":"2024","title":"Structure-based virtual screening and molecular dynamics approaches to identify new inhibitors of Staphylococcus aureus sortase A.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"33917313","year":"2021","title":"Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"3896262","year":"1985","title":"[Mutagenesis of efloxate tested in vitro and in vivo].","finding":"","journal":"Bollettino chimico farmaceutico","studyType":"Clinical Study"},{"pmid":"334448","year":"1977","title":"[Clinical research on the therapeutic efficacy and tolerance of long-acting efloxate in angina pectoris].","finding":"","journal":"La Clinica terapeutica","studyType":"Clinical Study"}],"tags":[{"label":"efloxate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C01DX13","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"oxiflavil","offLabel":[],"synonyms":["efloxate","flacethyle","oxiflavil","oxyflavil"],"timeline":[],"approvals":[],"brandName":"Oxiflavil","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"efloxate","explanation":"Think of Efloxate like a key that unlocks a specific process in the body. By blocking this process, Efloxate can help to reduce symptoms or treat certain conditions. However, the exact details of how Efloxate works are still not fully understood.","oneSentence":"Efloxate is believed to work by inhibiting a specific enzyme or pathway.","technicalDetail":"Efloxate's mechanism of action is thought to involve the inhibition of a specific enzyme or pathway, although the exact molecular details are currently unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/991","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EFLOXATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:56:52.029883","biosimilars":[],"competitors":[{"drugName":"nesiritide","drugSlug":"nesiritide","fdaApproval":"2001-08-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vericiguat","drugSlug":"vericiguat","fdaApproval":"2021-01-19","patentExpiry":"Nov 26, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"efloxate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nesiritide","brandName":"nesiritide","genericName":"nesiritide","approvalYear":"2001","relationship":"same-class"},{"drugId":"vericiguat","brandName":"vericiguat","genericName":"vericiguat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005411","UNII":"CZU6V3902K","CHEBI":"CHEBI:31531","INN_ID":"1452","RXNORM":"23852","UMLSCUI":"C0058961","ChEMBL_ID":"CHEMBL1349073","KEGG_DRUG":"D01135","DRUGBANK_ID":"DB13333","PUBCHEM_CID":"8395","MESH_SUPPLEMENTAL_RECORD_UI":"C005472"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C01DX13","allCodes":["C01DX13"]},"biosimilarFilings":[],"recentPublications":[{"date":"2024 Feb-Mar","pmid":"37184111","title":"Structure-based virtual screening and molecular dynamics approaches to identify new inhibitors of Staphylococcus aureus sortase A.","journal":"Journal of biomolecular structure & dynamics"},{"date":"2021 Apr 6","pmid":"33917313","title":"Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"1985 Mar","pmid":"3896262","title":"[Mutagenesis of efloxate tested in vitro and in vivo].","journal":"Bollettino chimico farmaceutico"},{"date":"1977 Aug 15","pmid":"334448","title":"[Clinical research on the therapeutic efficacy and tolerance of long-acting efloxate in angina pectoris].","journal":"La Clinica terapeutica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxiflavil, also known as Efloxate, is a small molecule drug in the efloxate class. Its exact target and mechanism of action are unknown, but it is believed to work by inhibiting a specific enzyme or pathway. Efloxate is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, key safety considerations and approved indications are currently unavailable.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}